MS trial withdrawn before it began: CAR T-Cell hope on hold
NCT ID NCT07006805
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test a new treatment called CABA-201, a CAR T-cell therapy made from a patient's own immune cells, for people with multiple sclerosis (MS). The goal was to see if it was safe and could control the disease by targeting and resetting the immune system. However, the trial was withdrawn before enrolling any participants, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CABA-201 (a type of CAR T-cell therapy made from the patient's own immune cells)
- What this could lead to
- If it worked, this could point toward a new way to control multiple sclerosis by resetting the immune system.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so no results exist. CAR T-cell therapy carries risks like cytokine release syndrome and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentle electric zap to the brain restore memory in MS?
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?